Phase 2 Open-Label Extension

Ongoing Phase 2 Open-Label Diffuse Cutaneous Systemic Sclerosis (Scleroderma) Study

Corbus received approval for an open-label extension to its double-blind, placebo-controlled, randomized Phase 2 clinical study of anabasum for systemic sclerosis from the U.S. Food and Drug Administration (FDA) in April 2016. The open-label extension enables all the participants who completed the double-blind portion of the study the option of enrolling in an open-label extension to receive anabasum twice a day for an additional 12 months. The goal of the open-label extension study is to collect long term safety and efficacy data on anabasum.

For more information, contact:

SSc patients contact:
Physicians contact:
Other inquiries:

Site Contact Principal Investigator

Arthritis Association of Southern California

800 W 6th St #1250
Los Angeles, CA 90017
United States

Ethan Zaccagnino

609-895-0735 ext 133

Daniel Furst, MD

Stanford University

300 Pasteur Dr
Stanford, CA 94305
United States

Joel Nicholus


Lorinda Chung, MD

John Hopkins Scleroderma Center

5501 Hopkins Bayview Cir
Baltimore, MD 21224
United States

Gwen Leatherman


Laura Hummers

Boston University Medical Center

1 Boston Medical Center Pl
Boston, MA 02118
United States

Christopher Zammitti


Robert W Simms, MD

Rutgers University

125 Paterson St
New Brunswick, NJ 08901
United States

Deborah McCloskey


Vivien Hsu, MD

Weill Cornell Medical College

1300 York Ave
New York, NY 10065
United States

Emily Bakaj


Robert Spiera

University of Pittsburgh Medical Center

1515 Locust St
Pittsburgh, PA 15219
United States

Dana Ivanco


Robyn T Domsic, MD

University of Utah

50 N Medical Dr
Salt Lake City, UT 84132
United States

Jennifer Godina


Tracy Frech, MD

University of Texas Houston Medical School

6431 Fannin, MSB 1150
Houston, TX 77030
United States

Patricia Gonzales


Maureen Mayes, MD